510(k) device
Hemosil Readiplas Tin
Instrumentation Laboratory CO · Test, Time, Prothrombin (GJS, Class II) · First FDA decision Mar 24, 2013, newest Mar 24, 2013Anemia, clotting and blood disordersStroke prevention in atrial fibrillation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "Hemosil Readiplas Tin"
MAUDE reports
0
Brand "Hemosil Readiplas Tin", since 2015
PubMed studies
0
Mentioning "Hemosil Readiplas Tin"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Hemosil Readiplas Tin
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- HEMOSIL READIPLAS TIN510(k)
K122584 · Decided Mar 24, 2013 · 212 days after receipt
Device type: Test, Time, Prothrombin (GJS) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Home Prothrombin Time/International Normalized Ratio (PT/INR) Monitoring for Anticoagulation ManagementNational determinationOn the books190.11Updated Nov 4, 2026
- Prothrombin Time (PT)National determinationOn the books190.17Updated Oct 1, 2026
- Prothrombin Time (INR) Monitor for Home Anticoagulation ManagementNational analysisReview closedCAG-00087RUpdated Sep 21, 2026
- Prothrombin Time and Partial Thromboplastin Time (Revision of ICD-9-CM Codes for Swelling of Limb)Coding analysisReview closedCAG-00201NUpdated Sep 15, 2026
- Prothrombin Time and Partial Thromboplastin Time (Revision of ICD-9-CM Codes for Pre-operative Examinations)Coding analysisReview closedCAG-00184NUpdated Sep 15, 2026
- Prothrombin Time and Fecal Occult Blood (Revision of ICD-9-CM Codes for Injury to Gastrointestinal Tract)Coding analysisReview closedCAG-00187NUpdated Sep 15, 2026
- Prothrombin Time (PT) NCD 190.17 (Addition of ICD-9-CM diagnosis code 197.7 Secondary Malignant Neoplasm of Liver)Coding analysisReview closedCAG-00404NUpdated Sep 15, 2026
- Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) tests (Removal of Unspecified Joint Replacements)Coding analysisReview closedCAG-00246NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Hemosil Readiplas Tin", any status and sponsor, newest update first.
No registered device study names "Hemosil Readiplas Tin".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Hemosil Readiplas Tin", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code GJS
12,207 reports: 11,507 malfunction, 644 injury, 34 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- HemosIL ReadiPlasTin, Part No. 0020301400Open, Classified
Z-1052-2022 · Started Apr 8, 2022
Reason given: Variable and out of specification QC results with HemosIL ReadiPlasTin. IL will remove all lots from the market and convert customers to an alternative prothrombin time (PT) reagent, specifically HemosIL RecombiPlasTin 2G.
Cause as FDA categorized it: Under Investigation by firm · Device type: Test, Time, Prothrombin (GJS)
- HemosIL ReadiPlasTin (20 mL), Part number 0020301400. An in vitro diagnostic thromboplastin reagent.Open, Classified
Z-0276-2022 · Started Oct 13, 2021 · Posted by FDA Nov 23, 2021
Reason given: The firm has received customer reports of performance issues with the affected lot, including increased imprecision, out of range quality controls, and prolonged sample results. If quality controls are not performed or do not pass for each vial of reagent, there is a potential risk of reporting an erroneous result.
Cause as FDA categorized it: Under Investigation by firm · Device type: Test, Time, Prothrombin (GJS)
Instrumentation Laboratory Co.
Z-0077-2019 · Started Aug 1, 2018
Reason given: There is a potential for increased imprecision, out of range quality controls and prolonged sample results.
Cause as FDA categorized it: Material/Component Contamination · Device type: Test, Time, Prothrombin (GJS)
1 more recall records with a free account
Published research
The most relevant PubMed records for "Hemosil Readiplas Tin"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code GJS.
- microINR SystemIline Microsystems, S.L. · 510(k) 2025
- CoaguChek XS Plus SystemRoche Diagnostics · 510(k) 2025
- Coag-Sense Prothrombin (PT) / INR Monitoring System for Patient Self-TestingCoagusense, Inc. · 510(k) 2022
- CoaguChek XS Pro SystemRoche Diagnostics · 510(k) 2018
- Hemosil Recombiplastin 2G (8 Ml Vial)Instrumentation Laboratory CO · 510(k) 2014
- Coaguchek Xs SystemRoche Diagnostics Corp. · 510(k) 2007
- Xprecia Prime Coagulation SystemUniversal Biosensors Pty, Ltd. · 510(k) 2024
- i-STAT PTplus Cartridge with the i-STAT 1 SystemAbbott Laboratories · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.